Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3528674 | 0.92 | AR (0.43) | ARHDAC1KIF11IGF1RPGR | |
| SCHEMBL3528870 | 0.87 | AR (0.40) | ARHDAC1KIF11IGF1RPGR | |
| SCHEMBL3523182 | 0.87 | AR (0.42) | ARHDAC1KIF11IGF1RPGR | |
| SCHEMBL3526309 | 0.86 | AR (0.54) | ARHDAC1PGR | |
| SCHEMBL3526165 | 0.81 | AR (0.52) | ARHDAC1PGR | |
| SCHEMBL3528740 | 0.80 | AR (0.50) | ARHDAC1PGR | |
| SCHEMBL3530691 | 0.79 | AR (0.52) | ARHDAC1PGR | |
| SCHEMBL3526385 | 0.79 | AR (0.45) | ARHDAC1KIF11IGF1RPGR | |
| SCHEMBL6523411 | 0.79 | AR (0.53) | ARHDAC1PGR | |
| SCHEMBL3532540 | 0.79 | AR (0.51) | ARIGF1RPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759366-B2 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2010-07-20 | — | — | US | disclosed |
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215728-A1 | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | GPR119, GIPR, LIPC | AR 536/4885HDAC1 487/4885KIF11 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.